Suppr超能文献

原发性胆汁性肝硬化和原发性硬化性胆管炎的当前概念

Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

作者信息

Sclair Seth N, Little Ester, Levy Cynthia

机构信息

Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.

Banner University Medical Center, Phoenix, Arizona, USA.

出版信息

Clin Transl Gastroenterol. 2015 Aug 27;6(8):e109. doi: 10.1038/ctg.2015.33.

Abstract

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress regardless of treatment. Bilirubin <1.0 and alkaline phosphatase <2.0 x the upper limit of normal at 1 year after treatment appear to predict 10-year survival. Ursodeoxycholic acid (UDCA) is the recommended treatment for PBC, and recent studies with obeticholic acid showed promising results for UDCA non-responders. Unlike PBC, no therapy has been shown to alter the natural history of PSC. The recommended initial diagnostic test for PSC is magnetic resonance cholangiopancreatography, typically showing bile duct wall thickening, focal bile duct dilatation, and saccular dilatation of the intra- and/or extrahepatic bile ducts. Immunoglobulin 4-associated cholangitis must be excluded when considering the diagnosis of PSC, to allow for proper treatment, and monitoring of disease progression. In addition to the lack of therapy, PSC is a pre-malignant condition and close surveillance is indicated.

摘要

原发性胆汁性肝硬化(PBC)和原发性硬化性胆管炎(PSC)是具有共同临床表现的慢性胆汁淤积性肝病。PBC的早期诊断和治疗可减缓疾病进展并减少移植需求。然而,三分之一的患者无论治疗与否都会进展。治疗1年后胆红素<1.0且碱性磷酸酶<正常上限的2.0倍似乎可预测10年生存率。熊去氧胆酸(UDCA)是PBC的推荐治疗药物,最近关于奥贝胆酸的研究对UDCA无反应者显示出有希望的结果。与PBC不同,尚无治疗方法被证明可改变PSC的自然病程。PSC推荐的初始诊断检查是磁共振胰胆管造影,通常表现为胆管壁增厚、局灶性胆管扩张以及肝内和/或肝外胆管的囊状扩张。在考虑PSC诊断时必须排除免疫球蛋白4相关性胆管炎,以便进行适当治疗和监测疾病进展。除了缺乏有效治疗方法外,PSC还是一种癌前病变,需要密切监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52e3/4816277/2629785fa2dd/ctg201533f1.jpg

相似文献

1
Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.
Clin Transl Gastroenterol. 2015 Aug 27;6(8):e109. doi: 10.1038/ctg.2015.33.
2
[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].
Radiologe. 2019 Apr;59(4):348-356. doi: 10.1007/s00117-019-0513-x.
3
Obeticholic acid for the treatment of primary biliary cholangitis.
Expert Opin Pharmacother. 2016 Sep;17(13):1809-15. doi: 10.1080/14656566.2016.1218471. Epub 2016 Aug 9.
4
Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Clin Rev Allergy Immunol. 2005 Apr;28(2):135-45. doi: 10.1385/CRIAI:28:2:135.
5
[Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Korean J Gastroenterol. 2020 May 25;75(5):246-256. doi: 10.4166/kjg.2020.75.5.246.
6
Chronic cholestatic diseases.
J Hepatol. 2000;32(1 Suppl):129-40. doi: 10.1016/s0168-8278(00)80421-3.
7
Management of cholestatic disease in 2017.
Liver Int. 2017 Jan;37 Suppl 1:123-129. doi: 10.1111/liv.13306.
8
[Cholestatic liver diseases].
Ther Umsch. 2004 Aug;61(8):521-7. doi: 10.1024/0040-5930.61.8.521.
9
Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital.
J Clin Exp Hepatol. 2023 Mar-Apr;13(2):241-251. doi: 10.1016/j.jceh.2022.11.002. Epub 2022 Nov 10.
10
Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: an Update on MR Imaging Findings with Recent Developments.
J Gastrointestin Liver Dis. 2016 Dec;25(4):517-524. doi: 10.15403/jgld.2014.1121.254.vac.

引用本文的文献

1
CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms.
Cells. 2025 Jan 13;14(2):105. doi: 10.3390/cells14020105.
3
A comparison of balloon- versus stent-based approach for dominant strictures in primary sclerosing cholangitis: a meta-analysis.
Ann Gastroenterol. 2022 May-Jun;35(3):307-316. doi: 10.20524/aog.2022.0701. Epub 2022 Mar 25.
5
Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.
Hepatobiliary Surg Nutr. 2020 Oct;9(5):587-596. doi: 10.21037/hbsn.2019.08.07.
6
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
Diseases. 2019 Nov 12;7(4):58. doi: 10.3390/diseases7040058.
7
Clinical profile and outcome of primary sclerosing cholangitis: A single-centre experience from western India.
Indian J Gastroenterol. 2019 Aug;38(4):295-302. doi: 10.1007/s12664-019-00968-1. Epub 2019 Sep 12.
8
Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study.
CMAJ Open. 2018 Dec 21;6(4):E664-E670. doi: 10.9778/cmajo.20180029. Print 2018 Oct-Dec.
9
Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies.
Int J Mol Sci. 2018 Oct 1;19(10):3003. doi: 10.3390/ijms19103003.
10

本文引用的文献

1
Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):296-306. doi: 10.1016/j.clinre.2015.02.011. Epub 2015 Apr 14.
2
ACG Clinical Guideline: Primary Sclerosing Cholangitis.
Am J Gastroenterol. 2015 May;110(5):646-59; quiz 660. doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.
4
Current research on the treatment of primary sclerosing cholangitis.
Intractable Rare Dis Res. 2015 Feb;4(1):1-6. doi: 10.5582/irdr.2014.01018.
5
Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis.
Am J Gastroenterol. 2015 Feb;110(2):299-309. doi: 10.1038/ajg.2014.433. Epub 2015 Jan 27.
6
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.
Gut. 2016 Feb;65(2):321-9. doi: 10.1136/gutjnl-2014-308351. Epub 2015 Jan 7.
7
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11.
8
New therapies for primary biliary cirrhosis.
Clin Rev Allergy Immunol. 2015 Jun;48(2-3):263-72. doi: 10.1007/s12016-014-8456-5.
9
Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1292-301. doi: 10.1111/apt.12979. Epub 2014 Oct 14.
10
Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.
Liver Int. 2015 Feb;35(2):642-51. doi: 10.1111/liv.12690. Epub 2014 Oct 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验